Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback